SPARC and prostate cancer: Similarly, the cysteine cathepsin K (cath-K) also cleaves SPARC in vitro and in vivo in its N-terminal acid domain, and in its extracellular Ca2+ binding domain in prostate cancer bone metastases, releasing a 10-kDa C-terminal fragment with unknown biological activity 61.